A July 2024 study published in JAMA Ophthalmology found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a higher risk of a rare eye condition known as "eye stroke," or non-arteritic anterior ischemic optic neuropathy (NAION). This condition can lead to sudden vision loss.1
Building on these findings, a new preprint study from Denmark and Norway has reaffirmed the association. Researchers found that people taking semgalutide were more than twice as likely to develop NAION compared to those using SGLT2 inhibitors, another type 2 diabetes medication.2